智通财经APP讯，白云山(00874)发布公告，近日，公司控股子公司广州白云山天心制药股份有限公司(简称“天心药业”)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，注射用头孢噻肟钠(0.5g、1.0g)已通过仿制药质量和疗效一致性评价。
注射用头孢噻肟钠为第三代头孢菌素抗生素，适用于敏感菌所致的下呼吸道感染、泌尿生殖道感染、妇科感染、菌血症/败血症、皮肤及皮肤软组织感染、腹腔感染、骨和关节感染、中枢神经系统感染。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.